Ceretype Neuromedicine Unveils Groundbreaking Methods to Quantify and Standardize Measures of Brain Activity at the 20th Annual Meeting of ISCTM

Ceretype Neuromedicine, a pioneer in practical application and integration of functional MRI (fMRI), presented new data at the 20th Annual Meeting of the International Society of CNS Clinical Trials and Methodology (ISCTM) in Washington DC on February 22nd.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, March 4, 2024
Information
Tags: 
Science, Neurology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Doctor of Philosophy, Neuropsychiatry, International Society, Central nervous system disease, Biomarker, CNS, Medicine, Poster, Magnetic resonance, MRI, Medical imaging
Geotags: 
UNITED STATES, NORTH AMERICA, DISTRICT OF COLUMBIA, MASSACHUSETTS
Organisation: 
CERETYPE NEUROMEDICINE
Summary
Key Points: 
  • Ceretype Neuromedicine, a pioneer in practical application and integration of functional MRI (fMRI), presented new data at the 20th Annual Meeting of the International Society of CNS Clinical Trials and Methodology (ISCTM) in Washington DC on February 22nd.
  • The poster, entitled ‘Quantitative, Standardized Brain Network Activity Measures to Inform CNS Treatment Development,’ was presented by co-first author, Roni Setton, PhD and can be found here .
  • “We are pleased to share the groundbreaking methodological work on a novel quantitative imaging strategy,” said Ceretype CTO, Prantik Kundu, PhD.
  • “The findings highlight advances in the sensitivity and reliability of measured brain signal, demonstrating that a robust, standardized measure of brain network activity can be derived from fMRI.


Ceretype Neuromedicine, a pioneer in practical application and integration of functional MRI (fMRI), presented new data at the 20th Annual Meeting of the International Society of CNS Clinical Trials and Methodology (ISCTM) in Washington DC on February 22nd. The poster, entitled ‘Quantitative, Standardized Brain Network Activity Measures to Inform CNS Treatment Development,’ was presented by co-first author, Roni Setton, PhD and can be found here.

“We are pleased to share the groundbreaking methodological work on a novel quantitative imaging strategy,” said Ceretype CTO, Prantik Kundu, PhD. “The findings highlight advances in the sensitivity and reliability of measured brain signal, demonstrating that a robust, standardized measure of brain network activity can be derived from fMRI. This paves the way for discovery of highly sensitive brain-based biomarkers for the development and long-term monitoring of new CNS treatments.”

“This evidence continues to establish Ceretype as a world leader in brain-based biomarker technologies for CNS disorders. I am proud of the solutions that our team has developed to address challenges that have plagued fMRI for decades, opening the door for precision medicine in neuropsychiatry,” said Ceretype’s Co-Founder & CEO Emily Stern, MD.

Since its founding in 2020, Ceretype has partnered with several pharmaceutical and biotech companies to quantitatively analyze the impact of their treatments on the functional networks within patients’ brains.

About Ceretype Neuromedicine

Ceretype has pioneered the practical application & integration of fMRI in neuropsychiatric drug development and beyond. Our uniquely scalable, next-generation, end-to-end platform makes targeted biomarkers accessible, delivering actionable evidence to improve drug discovery and, ultimately, patient care. Through its superior technical approach and its unique ability to sub-type and classify the human brain on a neurobiological level, Ceretype offers novel, precise, biologically-based therapeutic insights. For more information, please visit www.ceretype.com.

Copyright: 
Copyright Business Wire 2024